Skip to main content
SpringerLink
Log in

Hypoglycemia and insulin treatment

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011, 34: 1164–70.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Goetzel RZ, Ozminkowski RJ, Meneades L, Stewart M, Schutt DC. Pharmaceuticals-cost or investment? An employer’s perspective. J Occup Environ Med 2000, 42: 338–51.

    Article  CAS  PubMed  Google Scholar 

  3. Meneghini L, Liebl A, Abrahamson MJ. Insulin detemir: A historical perspective on a modern basal insulin analogue. Prim Care Diabetes 2010, 4(Suppl 1): S31–42.

    Article  PubMed  Google Scholar 

  4. Bolli GB, Owens DR. Insulin glargine. Lancet 2000, 356: 443–5.

    Article  CAS  PubMed  Google Scholar 

  5. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004, 53: 1614–20.

    Article  CAS  PubMed  Google Scholar 

  6. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26: 3080–6.

    Article  CAS  PubMed  Google Scholar 

  7. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005, 28: 950–5.

    Article  CAS  PubMed  Google Scholar 

  8. Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010, 12: 772–9.

    Article  CAS  PubMed  Google Scholar 

  9. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemirwith NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006, 28: 1569–81.

    Article  CAS  PubMed  Google Scholar 

  10. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemirwith NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006, 29: 1269–74.

    Article  CAS  PubMed  Google Scholar 

  11. Garber AJ, Clauson P, Pedersen CB, Kolendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc 2007, 55: 1735–40.

    Article  PubMed  Google Scholar 

  12. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011, 7: CD006383.

    PubMed  Google Scholar 

  13. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) fortype 2 diabetes mellitus. Cochrane Database Syst Rev 2007, 2: CD005613.

    PubMed  Google Scholar 

  14. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008, 81: 184–9.

    Article  CAS  PubMed  Google Scholar 

  15. Swinnen SG, Dain MP, Aronson R et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010, 33: 1176–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Fadini GP, de Kreutzenberg SV, Mariano V, et al. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes Obes Metab 2011, 13: 718–25.

    Article  CAS  PubMed  Google Scholar 

  17. Jonassen I, Havelund S, Ribel U, et al. Insulin Degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multihexamer formation. Diabetes 2010, 59(Suppl 1): A11 (abstract).

    Google Scholar 

  18. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargineonce a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011, 377: 924–31.

    Article  CAS  PubMed  Google Scholar 

  19. Atkin SL, Bain SC, Gough S, et al. Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes. Diabetologia 2011, 54(Suppl 1): S53 (abstract).

    Google Scholar 

  20. Hollander P, King AB, Francisco A, et al. Basal-bolus therapy with insulin degludec improves long-term glycemic control with fewer nocturnal hypoglycaemic events compared with insulin glargine in people with type 2 diabetes. Diabetologia 2011, 54(Suppl 1): S421 (abstract).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardio-Metabolism and Clinical Trials Unit, Metabolic and Cardiovascular Science Division, Department of Internal Medicine, San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy

    F. Febo, C. Molinari & P. M. Piatti MD

Authors
  1. F. Febo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Molinari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. M. Piatti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. M. Piatti MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Febo, F., Molinari, C. & Piatti, P.M. Hypoglycemia and insulin treatment. J Endocrinol Invest 34, 698–701 (2011). https://doi.org/10.1007/BF03345405

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345405

Key-words

Search

Navigation